Abstract: A drive system may include an internal combustion engine and an expander operated via a working medium. A force transmission device may be disposed between a crankcase and the expander. A first seal may be disposed between the expander and the force transmission device and/or a second seal may be disposed between the force transmission device and the crankcase. A crankcase ventilation line may lead from the crankcase into an intake pipe of the internal combustion engine. An air mass sensor may be disposed in the intake pipe. An engine control unit may be in communication with the air mass sensor, the expander, and the internal combustion engine and may be configured to detect a power of the internal combustion engine and an air mass flow of the air mass sensor and may switch off the expander if a power suddenly rises with the air mass flow remaining constant.

Abstract: A diffuser of a thermal energy machine, in particular of a gas turbine, has a diffuser inlet, a diffuser outlet, and a plurality of air-guiding elements, wherein an air mass flow enters the diffuser through the diffuser inlet, and wherein the air mass flow that has entered the diffuser exits the diffuser through the diffuser outlet and flows off as a plurality of partial air mass flows by the air-guiding elements. At least two immediately adjacent air-guiding elements of the plurality of air-guiding elements are designed in such a way that the flow-off angles thereof with respect to the circumferential surface formed by the outlet opening of the diffuser outlet extending circumferentially in the circumferential direction differ from each other.

Abstract: Compounds of formula (IIc); wherein X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different; Y1, Y2, Y3 and Y4 independently from each other are N or CR9 wherein R9 may be same or different and wherein up to 3 of the group Y1, Y2, Y3 and Y4 may be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

Abstract: Apparatus for heating plastic preforms, having a microwave generating device which generates microwaves, and having a resonator device which forms a receiving space into which the plastic preforms can be introduced so as to be acted upon by the microwaves in the resonator device in order to be heated, wherein the apparatus has a reflector element which is arranged at least partially in the receiving space and which is suitable and intended for conducting microwaves in the direction of a base region of the plastic preforms. According to the invention, the reflector element is movable relative to the receiving space and the apparatus has a drive device for moving the reflector element relative to the receiving space.

Abstract: Compounds of formula (IIc); wherein X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different; Y1, Y2, Y3 and Y4 independently from each other are N or CR9 wherein R9 may be same or different and wherein up to 3 of the group Y1, Y2, Y3 and Y4 may be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

Abstract: The present invention relates to compounds having the general formula (I) with the definitions of X1-X3, Y1, Y2, L1, R1 and R2 given below and/or solvates, hydrates, esters and pharmaceutically acceptable salts thereof. Furthermore, the invention relates to the use of said compounds for modulating of the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

Abstract: Compounds of formula (IIc); wherein X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different; Y1, Y2, Y3 and Y4 independently from each other are N or CR9 wherein R9 may be same or different and wherein up to 3 of the group Y1, Y2, Y3 and Y4 may be N; their solvates, hydrates, and pharmaceutically acceptable salts, their use for modulating the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.

Abstract: Compounds according to the general formula (I) wherein X1, X2, X3 and X4 independently from each other are N or CR8 wherein R8 may be same or different, and wherein up to 3 of the group X1, X2, X3 and X4 may be N; A is a 5- or 6-membered aromatic or heteroaromtic cycle containing 1 to 3 heteroatoms selected from the group consisting of N, O and S wherein A may be substituted by 1 to 5 substituents R which may be same or different; their solvates, hydrates, and pharmaceutically acceptable salts for the treatment of a disorder or disease associated with an aberrant activation of Wnt signalling in a mammal selected from a cell proliferative disorder, rheumatoid arthritis, increased bone density, aging or age-related disorders and/or diseases or Dupuytren disease (superficial fibromatosis).

Abstract: The present invention relates to compounds having the general formula (I) with the definitions of X1-X3, Y1, Y2, L1, R1 and R2 given below and/or solvates, hydrates, esters and pharmaceutically acceptable salts thereof. Furthermore, the invention relates to the use of said compounds for modulating of the Wnt signalling pathway activity and their use as a medicament, preferably for the treatment of cancer.